NCT07112144招募中3 期
Phase III Clinical Trials to Evaluate the Immunogenicity and Safety of Adsorption-free Diphtheria and Tetanus (Three-component) Combined Vaccine in 2-month-old Infants and Young Children
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,650
- 试验地点
- 1
- 主要终点
- Immunogenicity
研究概览
简要总结
The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Months 至 3 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy infants and young children who are permanent residents aged 2 months (60-89 days), and can provide valid identification documents for the subject and their legal guardian;
- •Obtain the informed consent of the subject's legal guardian and sign the informed consent form;
- •The legal guardian of the subject can comply with the requirements of the clinical trial protocol.
排除标准
- •History of pertussis, diphtheria, or tetanus;
- •Contact with individuals diagnosed with pertussis or diphtheria within the past 30 days;
- •Vaccination with vaccines containing DTaP components, inactivated poliovirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine, or Hib vaccine;
- •Premature infants (born before 37 weeks of gestation), infants with severe abnormal labor processes or a history of asphyxia rescue, or low birth weight infants (<2500g);
- •Axillary temperature >37.0°C on the day of enrollment*;
- •Severe congenital malformations or developmental disorders, genetic defects, severe malnutrition, or congenital diseases (such as Down syndrome, sickle cell anemia, congenital nervous system diseases, etc.);
- •History of epilepsy, convulsions, or seizures, history of cerebral palsy, or family history of mental illness;
- •Autoimmune diseases or immunodeficiencies (such as perianal abscesses suggesting possible immunodeficiency in infants, human immunodeficiency virus infection, lymphoma, leukemia, etc.), or parents/siblings with autoimmune diseases or immunodeficiencies;
- •Asplenia or splenic dysfunction due to any cause;
- •Clinically diagnosed coagulation disorders (such as coagulation factor deficiencies, coagulation diseases, platelet abnormalities) or obvious bruising/coagulation disorders that may contraindicate intramuscular injection;
- •History of severe allergic diseases (such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrotic reactions), history of severe allergic reactions to any vaccine (widespread urticaria, angioedema, etc.), or allergy to any known component of the test vaccine (pertussis toxoid, filamentous hemagglutinin, 69KD outer membrane protein, diphtheria toxoid, tetanus toxoid, aluminum hydroxide, sodium chloride, sodium hydroxide, etc.);
- •Vaccination with subunit or inactivated vaccines within the past 7 days; vaccination with live attenuated vaccines within the past 14 days*;
- •Receipt of immunoglobulin and/or any blood products (except hepatitis B immunoglobulin) before enrollment;
- •Receipt of any immunostimulant or immunosuppressant therapy before enrollment (continuous oral administration or infusion for ≥14 days, or topical steroid use [inhaled, nasal spray, intra-articular, eye drops, ointments, etc.] exceeding the recommended dosage in the package insert);
- •Suffering from acute illnesses within 3 days before enrollment (acute illness is defined as moderate or severe illness with or without fever)*;
- •Administration of prophylactic medications (such as antipyretic analgesics, antiallergic drugs, antidiarrheal drugs, etc.) within 3 days before enrollment*;
- •Known or suspected severe clinically diagnosed diseases (including but not limited to severe diseases of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal systems, as well as a history of malignant tumors);
- •Currently participating in other clinical trials or planning to participate in other trials during the study period;
- •Any other factors that, in the judgment of the researcher, make the subject unsuitable for participating in the clinical trial.
研究组 & 干预措施
DTacP
Experimental
干预措施: DTacP (Biological)
DTaP
Active Comparator
干预措施: DTaP (Biological)
DTacP-IPV/Hib
Active Comparator
干预措施: DTacP-IPV/Hib (Biological)
结局指标
主要结局
Immunogenicity
时间窗: day 30 post-primary immunization
Seroconversion rates of anti-PT, anti-FHA, anti-PRN, anti-DT, and anti-TT antibodies at day 30 post-primary immunization
次要结局
- Immunogenicity(day 30 post-fourth booster immunization)
- Safety(At 12 months post-complete vaccination series)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAIRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300
进行中（未招募）
1 期
Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000
已完成
3 期
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.CTRI/2009/091/000767Merck Sharp and Dohme2,800
进行中（未招募）
3 期
This study will evaluate the immunogenicity and tolerability of V503 ipreadolescent and adolescent subjects between 9 and 15 years old andemonstrate the consistency of the manufactured vaccine throughassessment of 3 different final manufacturing process lots of V503.CTRI/2013/09/004012Merck Sharp and Dohme2,800
进行中（未招募）
1 期
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)Cervical CancersVulvar CancerVaginal CancerGenital LesionsPAP Test AbnormalitiesHPV InfectionsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.